Traders load up on bullish bets ahead of Nvidia’s earnings
BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX) announced Tuesday it will present preclinical data on its cancer drug candidate CTX-10726 at the Society for Immunotherapy of Cancer Annual Meeting taking place November 5-9, 2025. The clinical-stage biopharmaceutical company, currently valued at approximately $642 million, is scheduled to release its quarterly earnings report in just two days on November 6, according to InvestingPro data.
The bispecific antibody simultaneously targets vascular endothelial growth factor (VEGF)-A and programmed cell death (PD)-1, potentially addressing both tumor angiogenesis and immune suppression.
According to the company's press release statement, CTX-10726 demonstrated high-affinity binding to both VEGF-A and PD-1 in laboratory tests, effectively blocking their interactions with their respective receptors.
In preclinical studies, the drug candidate showed superior anti-tumor efficacy compared to ivonescimab and an anti-VEGF-A antibody in a human lung cancer model. It also demonstrated stronger anti-tumor activity against human-PD-L1 expressing colon cancer cells compared to ivonescimab in specialized mouse models.
The company reported that CTX-10726 significantly reduced tumor size compared with bevacizumab in mice implanted with human-PD-1 and VEGF-A expressing colon cancer cells.
Compass Therapeutics is developing CTX-10726 for treatment of patients with metastatic or locally advanced tumors where both checkpoint and angiogenesis signals are present.
The clinical-stage biopharmaceutical company confirmed that an Investigational New Drug (IND) submission remains on track for the fourth quarter of 2025.
The poster presentation is scheduled for November 7 at the Gaylord National Resort & Convention Center.
In other recent news, Compass Therapeutics reported a net loss of $19.9 million for the second quarter of 2025, with earnings per share at $(0.14), slightly surpassing Raymond James' expectations. The company concluded the quarter with approximately $101 million in cash, anticipated to sustain operations into 2027. Additionally, Compass Therapeutics announced the pricing of a public offering, expected to raise around $120 million, consisting of 33,290,000 shares priced at $3.00 each and pre-funded warrants for additional shares. The offering aims to strengthen the company's financial position, with no shares being sold by existing shareholders.
In terms of analyst ratings, Piper Sandler reiterated an Overweight rating with a $12.00 price target, while Guggenheim increased its price target from $10.00 to $12.00, maintaining a Buy rating. Raymond James also continued to hold an Outperform rating with a $9.00 price target. The clinical trial timeline for the COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer has been adjusted, with final analysis now expected in the first quarter of 2026. These developments reflect ongoing progress in Compass Therapeutics' clinical and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.